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hepatocytes and secretion of proinﬂammatory cytokines
IFNg and TNFa to inhibit HBV replication noncytolytically.
Since these inhibitory cytokines are produced not only
by CTL, but also by enriched, activated populations of
hepatic NK and NKT-cells, it is now clear that NK and
NKT-cells contribute to resolution of acute hepatitis B.
HBV-speciﬁc T-cell immune responses are also modulated by
CD4 T regulatory cells. The role of HBV-speciﬁc antibodies
in resolution is less clear; however, once acute infection
is resolved the combination of HBV-speciﬁc cellular and
humoral immunity prevents reactivation of HBV replication
from residual nuclear cccDNA templates. The risk of
reactivation remains if immunological control is disrupted
by immunosuppressive drugs or cytoablative chemotherapy.
Persistent HBV infection, which occurs in the majority
of neonates and infants but only a minority of adults,
is favored by several viral and host factors. The viral
factors include the subversion of innate immunity, a high
rate of replication favoring mutational escape, absence
of hepatocyte gene induction, tolerogenic properties of
secreted HBeAg and HBsAg, HBx inhibition of proteasome
processing of antigens and HBx induction of aberrant
class II MHC and ICAM-1 to favor clonal T-cell anergy
due to absence of costimulatory signaling. Host factors
associated with persistence include decreased numbers
and defective function of plasmacytoid-dendritic cells,
decreased expression of TLR and class I MHC, decreased
production of MDL and APOBEC3 cytidine deaminases,
CTLA-4 polymophorisms, CD4 T regulatory cell activity and
CTL suppression mediated by paracrine activation of PD-1.
Overall, chronic hepatitis B is associated with a paucity
of HBV-speciﬁc CTL, activated HBV-speciﬁc CD4 T helper 1
cells and hepatic inﬂammatory inﬁltrates enriched for NK,
NKT and other antigen-nonspeciﬁc cells. Perpetuation of
antigen-nonspeciﬁc inﬂammation favors progressive ﬁbrosis.
Better understanding of the immunopathogenesis of HBV
infection has also provided insights into the mechanisms
responsible for ﬂares during chronic infection, reactivation
following immunosuppression or chemotherapy, vasculitis
and recurrent HBV infection after liver transplantation.
Ultimately, complete understanding of the immunology of
HBV infection will likely lead to new therapeutic strategies.
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Hepatitis B virus (HBV) infection is a worldwide health
problem. Understanding of the HBV life cycle especially the
replication mechanism may provide potential targets for
the development of anti-HBV treatment. Cell culture and
animal models with HBV replication are the most important
tools for studies on the mechanism of HBV replication, the
pathogenesis of HBV-related liver diseases, and the selection
of anti-HBV drugs.
Hepatotropism is a prominent feature of hepatitis B virus
(HBV) infection. Cell lines of non-hepatic origin do not
independently support HBV replication hepatic origin. In
our study, a new HBV nonhepatoma cell replication system
has been developed where pregenomic RNA synthesis
and consequently HBV replication are controlled by the
ectopic expression of liver-enriched transcription factors.
We show that the nuclear hormone receptors, hepatocyte
nuclear factor 4 (HNF4) or retinoid X receptor a (RXRa)
plus peroxisome proliferator-activated receptor a (PPARa),
support HBV replication in non-hepatic cells, indicating
these liver-enriched transcription factors represent a major
determinant governing the hepatotropism of HBV. With
this new HBV replication system, many roles of the
liver-enriched transcription factors in controlling HBV
transcription and replication have been identiﬁed.
Until recently, most in vivo studies on HBV have been
performed by using HBV transgenic mice. However, the
acquisition of transgenic mice is very time-consuming and
laborious, because expensive microinjection equipment and
complicated technology is needed. Recently, we developed
a new mouse model with HBV replication by using a
hydrodynamic procedure that provides a simple, convenient
and useful tool for molecular-biological studies on HBV, and
for the selection of anti-HBV drugs.
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Aims: Epidermal growth factor (EGF) is a multifunctional
growth factor, and plays an important role in tumorigenesis,
including hepatocellular carcinoma (HCC). A single
nucleotide polymorphism (SNP) at position 61 in the 5′-
untranslated region (UTR) of the EGF gene has been
reported to modulate the transcription level of this gene
and is associated with the level of EGF protein expression in
serum or plasma. In present study the relationship between
EGF 61A/G polymorphism, EGF protein expression level,
and risk of HCC in patients with hepatitis B virus chronic
infection were assessed.
Materials and Methods: EGF gene 61A/G allele was
genotyped in ten human HCC cell lines and one immortalized
normal liver cell line. Furthermore, genomic DNA samples
from 195 HCC patients, 149 cirrhosis patients, and 186
healthy control subjects were also examined. Polymerase
chain reaction restriction fragment-length polymorphism
(PCR-RFLP) was used to determine the EGF polymorphism
genotype. EGF protein in different polymorphism genotype
from healthy control subjects was quantiﬁed by using an
enzyme-linked immmunosorbent assay (ELISA). HCC cell
lines with different polymorphic genotype were subjected
to growth assay in the presence of geﬁtinib, one EGFR
blocker.
Results: Six of the examined HCC cell lines were GG
genotype (HBxF344, Hep3B, SKHep1, SNU182, SNU387 and
SNU449), 3 were GA genotype (HepG2, PLC/PRF5 and
SMMC7721), SNU475 and the immortalized LO2 was AA
genotype. Allele frequencies of EGF SNP61*A and SNP61*G
in control group were 28.76% and 71.24%, while they
were 27.18% and 72.82%, 32.89% and 67.11% in HCC group
and cirrhosis group respectively. There was no signiﬁcant
difference in SNP61*A frequencies between hepatocellular
carcinoma group and healthy control group, as well as
cirrhosis group and healthy control group. And SNP61*A
frequencies in HCC group have no difference from cirrhosis
group, however, patients with a GA or GG genotype
had a respectively 2.3- and 1.9-fold odds of developing
hepatocellular carcinoma compared with patients with the
AA genotype, indicating that AA genotype may have lower
HCC risk. Concordantly, a signiﬁcant higher EGF protein
level in GG and GA genotype compared to AA genotype was
found. In addition, EGF gene polymorphisms at position 19,
101, 341 were also examined from 78 healthy subjects, 53
HCC patients, all were homozygote. In order to conﬁrm
whether EGFR blocker can affect the proliferation of cell
with different genotypes, six cell lines were treated by
geﬁtinib. We observed that cell proliferation of HBxF344,
SKHep1 with the GG genotype was reduced by geﬁtinib
